News & Events about Oncorus Inc.
Globe Newswire
2 months ago
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate ...
Globe Newswire
2 months ago
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 ...
Globe Newswire
3 months ago
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on stimulating the immune system to transform outcomes ...
Globe Newswire
9 months ago
ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration vRNA Immunotherapy Platform has the potential to address challenges associated with IV-administered RNA-based oncology therapeutics Oncorus is advancing ONCR-021 into clinical development, with IND ...
HC Wainwright assumed coverage on shares of Oncorus (NASDAQ:ONCR Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued a buy rating and a $7.00 target price on the stock. A number of other analysts have also commented on the company. Zacks Investment ...